Atezolizumab plus bevacizumab beyond first-line in hepatocellular carcinoma

Friedrich Sinner,Matthias Pinter,Bernhard Scheiner,Thomas Ettrich,Niklas Sturm, MariaA. Gonzalez-Carmona,Oliver Waidmann,Fabian Finkelmeier,Vera Himmelsbach, EnricoN. de Toni, Najib Ben-Khaled,Raphael Mohr, ThorbenWilhelm Fründt,Fabian Kütting,Florian van Bömmel, Sabine Lieb,Sebastian Krug,Dominik Bettinger,Michael Schultheiß,Leonie Jochheim,Jan Best,Verena Keitel,Christian Müller,Marino Venerito

39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der LeberZeitschrift für Gastroenterologie（2023）

引用 0|浏览0

暂无评分

摘要

Introduction Atezolizumab plus bevacizumab (atezo/bev) is the standard of care in first-line systemic therapy for advanced stage hepatocellular carcinoma (aHCC). Data on efficacy and safety of atezo/bev in patients with aHCC who received previous systemic therapy are not available.

查看译文

关键词

hepatocellular carcinoma,bevacizumab,first-line

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要